Skip to main content

From Psych Congress and Psych Congress Regionals

Neuropsychiatry

VIDEO
Martha Sajatovic, MD, provides details of a study which found that deutetrabenazine was effective as a treatment for tardive dyskinesia both in patients aged less than 55 years and in patients aged…
Deutetrabenazine offers long-term benefit for patients with severe tardive dyskinesia (TD), according to results from a 3-year open-label extension trial presented in a poster at Psych Congress 2020.
Adverse events in patients treated with deutetrabenazine were more common during titration than maintenance, a finding that provides “important context for the dosing schedule to providers and…
A decrease of 3 points on the Abnormal Involuntary Movement Scale score is the minimal clinically important difference for treatment of tardive dyskinesia with deutetrabenazine, according to a poster…
Psych Congress 2020 speaker Marc E. Agronin, MD, shares strategies that mental health clinicians can use to adjust psychopharmacologic treatment and dosages for geriatric patients.
Bernhard T. Baune, PhD, MD, head of the Department of Mental Health at the University of Münster, Germany, discusses the occurrence of cognitive deficits in patients with various psychiatric…
Bernhard T. Baune, PhD, MD, discusses the prevalence of cognitive dysfunction in people with major depressive disorder. Dr. Baune, of the University of Münster, Germany, spoke at the Psych Congress…
Back to Top